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Abstract 
 
Backgrounds: The terms frontotemporal lobar degeneration (FTLD) indicate a large set of 
neurodegenerative diseases, heterogeneous in their genetic, pathologic and clinical aspects.  
Objectives: This review will focus on the most recent contribution of neuroimaging tools on the 
diagnosis, characterization and pathogenesis of FTLD.  
Data sources: PubMed, Scopus, Ovid.  
Study eligibility criteria: recent papers published in English in the last 3 years. 
Results: We found 91 papers of interest and reviewed their contents, finding in particular 4 major 
topics: the contribution of neuroimaging on the differential diagnosis; patients’ functional 
characterization; new neuroimaging tools under development and presymptomatic genetic forms. 
Conclusions: Neuroimaging techniques have shown to be useful supporting tools in diagnosis, even 
if not always determinant to reach a conclusive decision, and quite important to identify 
phenocopies. At the moment there is not a neuroimaging biomarker that could track the progressive 
course of dementias and the effect of therapies, but it is possible that in the future Diffusion Tensor 
Imaging and molecular imaging could fill this void. Monitoring in vivo the evolution of the 
pathology for at least 5 years is essential, which would only be possible in a large multicentric 
study, while asymptomatic forms would require even longer observation periods. 
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Introduction 
The terms frontotemporal lobar degeneration (FTLD) indicate a large set of neurodegenerative 
diseases, very heterogeneous in their genetic, pathologic and clinical aspects 
1
 that selectively 
targets the frontal and temporal brain lobes, which become progressively hypoperfused and 
atrophic. In the last 3 years the scientific community has shown an exponentially increasing interest 
in describing and characterizing FTLD. It is however still unclear whether the different genetic, 
clinical and pathological manifestation of FTLD are different expressions of a single underlying 
condition or if they are different pathologies that damage the same groups of cerebral areas or 
functional networks. 
While FTLD is rarer than AD, it is the second cause of presenile dementia (< 65 years) and 
therefore of great interest, considering the social and economic costs of the loss of functionality. In 
60% of FTLD patients the onset is between 45 and 64 years, in 10% before 45 years and in 30% 
after 65th year of life 
2
. Overall, FTLD is the third most common cause of dementia after AD and 
Dementia with Lewy bodies (DLB) and constitutes 5-10% of all dementias confirmed by 
histopathological examination. The incidence of FTLD is estimated to be 3 to 4 per 100000 person-
year, its prevalence in the 45-64 years population is 15-22 per 100000 in the USA, 15 per 100000 in 
the UK and 22 per 100000 in Italy 
2
. The progression of the disease is on average 7-11 years, and 
the diagnosis usually is formulated 3-4 years after the onset. The average survival from the onset (9-
11 years) is extremly variable between different forms, with some patients that can live more than 
20 years 
2–4
. The main causes of death are cardiopulmonary collapse and cachexia. 
The main clinical variants of FTLD 
1
 are the behavioral (bvFTD, behavior variant FTD) and the 
linguistic ones (Primary Progressive Aphasia, PPA). PPA can be categorized in 3 subtypes 
5,6
: the 
non-fluent/agrammatic variant, also called progressive non-fluent aphasia (nfPPA or PNFA), 
semantic dementia or semantic variant (SD o svPPA), logophenic variant or logophenic progressive 
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aphasia (lvPPA o LPA). Table I report the main clinical characteristics of the different variants of 
FTLD (lvPPA was not reported as generally is associated with AD). 
 
Table I. Clinical features of FTLD 
Syndrome Behaviour Cognition Functional ability 
Motor 
symptoms 
bvFTD 
Disinhibition; apathy; 
loss of empathy; 
stereotyped behaviours; 
hyperorality 
Executive deficits; 
impaired social 
cognition; 
lack of insight 
Activities of daily living 
impaired by executive 
dysfunction, impaired 
persistence and impulse 
control 
Signs of PSPS, 
CBS or MND 
nfPPA 
 
Relative intact until 
late 
Non fluent language 
production, some 
anomia 
Activities of daily living 
impaired by deficits of verbal 
communication 
Signs of PSPS, 
CBS or MND; 
apraxia of speech 
svPPA 
 
Loss of empathy; 
mental rigidity; 
ritualistic behavior; 
dietary change 
Impaired linguistic 
comprehension, some 
anomia 
Activities of daily living 
impaired by semantic deficits 
and problems with planning 
Intact until late 
Adapted from 7, bvFTD = behavioral variant frontotemporal dementia, nfPPA = non fluent variant primary progressive 
aphasia, svPPA = sementic variant primary progressive aphasia, PSPS = progressive supranuclear palsy syndrome, CBS 
= corticobasal syndrome, MND = motor neurone disease 
 
 
From a neuropathological point of view, FTLD can be classified by the accumulated protein (tau, 
TDP-43, FUS, other) and divided into subtypes by considering the characteristics of the protein 
agglomerates 
8
. In particular, proteins described in the previous sections are involved in 90-95% of 
cases: FTLD-tau accounts for 40% of cases, FTLD-TDP accounts for 40-50% of cases and the 
FTLD-FUS accounts for 5-10% of the remaining cases. 
In about 40% of cases there is familiarity for FTLD, but only in 10-30% of the cases it is possible to 
identify an autosomal dominant transmission of the illness. To the present day several genes whose 
mutation is linked to FTLD have been identified, and the main three are: i) chromosome 9 open 
reading frame 72 (C9ORF72), ii) microtubule-associated protein tau (MAPT) and iii) progranulin 
(GRN). Taken together, these three mutations explain about 80% of autosomal dominant familial 
cases 
9
.  
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Diagnosis of FTLD is often complicated, and generally the diagnostic criteria for FTLD are 
articulated on three levels (see 
10
 for bvFTD validated consensus diagnostic criteria and 
11
 for some 
useful indications about PPA): for a possible diagnosis there must be behavioral and/or 
neuropsychological changes, for a probable diagnosis there is the additional requirement of cortical 
alteration demonstrated by neuroimaging (Computed Tomography, CT; Magnetic Resonance 
Imaging, MRI; Positron Emission Tomography, PET; Single Photon Emission Computerized 
Tomography, SPECT). To reach the certainty of the diagnosis, there must be either 
neuropathological or genetic findings suggestive of FTLD. 
Even when strictly abiding by the diagnostic criteria, clinical diagnosis of possible FTLD contain 
up to 10-20% of undiagnosed AD cases, as AD can have atypical onsets 
12
. Different variant of 
FTLD can coexist in their clinical progression and comorbidity with motor symptoms and 
neurodegenerative disease as Motor Neuron Disease (MND), in particular Amyotrophic Lateral 
Sclerosis (ALS), or atypical parkinsonisms 
13
 as Corticobasal Syndrome (CBS), or Progressive 
Supranuclear Palsy Syndrome (PSPS).  
Considering all these diagnostic challenges, every serious tentative of diagnosis should be 
supported by a neuroimaging demonstration of frontal or temporal involvement. 
Another reason to consider the clinical description not sufficient to identify FTLD is the existence 
of phenocopies 
14
: that are patients (generally males) with symptoms that closely mimic bvFTD, but 
with a positive prognosis and relatively stable clinical pictures. The majority of studies, focused on 
discriminating different clinical subgroups or groups with different dementias (FTLD, DLB and 
AD) with neuroimaging, achieved good or excellent results 
15
. A focal brain involvement of the 
frontal and temporal lobes, typically hypoperfusion or atrophy, but also other kind of alterations 
(e.g. hypometabolism, white matter damage, etc…), is an important supportive element to a correct 
diagnosis. 
Currently there is not a clear understanding of the etiopathogenesis of this disease, nor medications 
or treatments able to cure, but some drugs that could act on pathogenic mechanisms are under 
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investigation. While waiting for more effective therapeutic tools, the main goal of the scientific 
community is to better understand the pathology and to obtain useful markers for early diagnosis 
9
.  
This review of the literature was systematic, but qualitative, and focused on the last 3 years 
publications about FTLD and clinical neuroimaging, a topic chosen for its relevance and 
newsworthy.  
 
Methods 
We followed the PRISMA guidelines recommendations for the search, the selection and the 
reporting of the relevant papers. We chose to use the following scientific references resources: 
Scopus, Ovid, PubMed and MEDLINE. We searched for articles published from January 2012 up to 
December 2014 (time limits), using combinations of the following keywords MeSH: 
Frontotemporal Lobar Degeneration; Diagnostic imaging; Neuroimaging; Image Interpretation, 
Computer-Assisted; Tomography, Emission-Computed; Tomography; Magnetic Resonance 
Imaging. Searches were limited to articles published in English. Frontotemporal Lobar 
Degeneration was always in the search queries in combination with logic AND with at least one 
other keyword. All the queries were pooled together, removing the duplicates. The resulting 
references were screened to keep only the papers concerning clinical neuroimaging. Further 
references were retrieved manually by reviewing the bibliographies of the relevant publications.  
 
Results  
We found 528 papers through database searching and 12 more by looking at the references of the 
final selection. The number of records was 243 after removing duplicate entries and 146 records 
were excluded after looking as the titles and/or abstracts were not focused on clinical neuroimaging 
and FTLD (Fig. 1). 
7 
 
Figure 1. Flow diagram of studies selection for the current review. 
 
The selected literature was classified in 4 groups: 
1) The contribution of neuroimaging on the differential diagnosis of FTLD; 
2) FTLD patients characterization with neuroimaging; 
3) New neuroimaging tools under development for FTLD study; 
4) The importance of the study of FTLD presymptomatic genetic forms. 
 
Ninety-seven full-text articles were assessed for eligibility and 6 were discarded as not pertinent or 
not fitting in the 4 topics classification (Fig. 1). 
Table II reports the level of evidence of the all 91 selected articles, according to the Oxford Centre 
for Evidence-based Medicine classification (March 2009, http://www.cebm.net/oxford-centre-
evidence-based-medicine-levels-evidence-march-2009). 
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Table II. Level of evidence of articles 
LOE Reference number(s) 
2a 8,10,28,30,74,79 
2b 3,4,11,12,19,20,24,25,26,29,31,33,34,38,40,41,44,49,51,55,71,80,84,86 
3a 1,6,15,16,56,59,61 
3b 17,18,21,22,23,27,45,46,47,50,52,53,54,58,62,65,66,67,70,72,73,76,81,82,87 
4 32,35,36,37,39,42,43,48,57,60,63,68,69,78,83,88,89,90,91 
5 2,5,7,9,13,14,64,75,77,85 
LOE = Level of Evidence from Oxford Centre for Evidence-based Medicine (March 2009)                  
http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009 
 
The reviewed studies were classified as 2a (7%), 2b (26%), 3a (8%), 3b (27%), 4 (21%) and 5 (11%). 
Discussion 
Differential diagnosis  
The atrophy pattern in FTLD is usually more anterior and asymmetric than in AD. Table III reports 
the areas more interested by the different clinical, genetic and pathological forms 
16
. While these 
patterns can be common, it is important to keep in mind that the variability within a single category 
(clinical, genetic or pathological) can be quite significant, as shown by a study 
17
 that analyzed 66 
subjects clinically diagnosed with bvFTD found 4 different atrophy patterns: frontal (21 subjects), 
temporal (6 subjects), fronto-temporal (12 subjects) and fronto-temporo-parietal one (27 subjects).  
It should constantly be remembered that there can be partial overlap between pathologies and MRI 
alone could not be enough to make a diagnosis. For instance, a paper analyzing cortical thickness 
18
 
of 36 AD and 24 FTLD, did not find any significant differences between the groups. Furthermore, 
studying the shape and the volume of hippocampus or temporal areas is extremely predictive of a 
neurodegenerative disease, but is not enough, when considered on its own, to discriminate between 
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AD and FTLD 
19,20
. While a thorough study of hippocampus and his sections can discriminate 
between different clinical forms, global indexes that can summarize the degree of anterior and 
posterior damage and of asymmetry can be more useful in clinical practice 
21
. 
 
Table III. Atrophy patterns in clinical, genetic, pathological variants of FTLD 
 PFC PMC TL med TL lat PL OL STR CRB LR 
Clinical          
bvFTD +++ + ++ ++ + − + − - 
nfPPA − ++ − − − − + − y 
svPPA + − +++ +++ − − + − - 
Genes          
MAPT ++ − +++ +++ + − + − - 
GRN ++ − + ++ ++ − − + y 
C9orf72 +++ ++ + ++ ++ + + ++ - 
Tau          
PiD +++ + ++ ++ + − + − y 
PSP − + − − − − + + - 
CBD + ++ − − + − ++ − - 
TDP          
TDP A +++ − + ++ ++ − − + y 
TDP B ++ + + + − − + − - 
TDP C + − +++ +++ − − + − y 
FUS ++ − + + − − +++ − - 
Adapted from 16, bvFTD = behavioral variant frontotemporal dementia, nfPPA = non fluent variant primary progressive 
aphasia, svPPA = sementic variant primary progressive aphasia, PiD = Pick’s disease, PSP = progressive supranuclear 
palsy, CBD = corticobasal degeneration. Atrophy graded as: relatively spared (−), mildly involved (+), moderately 
impaired (++), severely impaired (+++). PFC = prefrontal cortex; PMC = premotor cortex; TL = temporal lobe, med = 
medial, lat = lateral; PL = parietal lobe; OL = occipital lobe; STR = striatum; CRB = cerebellum. LR y = atrophy 
associated with left/right asymmetry. 
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The existence of typical atrophy patterns brought to the creation of automatic classificators, able to 
discriminate with good or excellent accuracy (> 80%) between two diagnostic categories (AD from 
controls, AD from FTLD and so on). The main shortcoming of these systems is their lack of 
applicability in a real clinical setting, as often they do not communicate to the medical operator the 
criteria used to determine the classification 
22
. 
The criteria should also not be too abstract, and the classificators should not be limited to a clear-cut 
binary choice, but be able to decide between multiple plausible diagnostic hypotheses. A recent 
attempt was made to create a real three classes classifier 
23
 able to discriminate AD, FTLD and 
healthy controls. 
A good index to discriminate 
24,25
 bvFTD from AD is given by the MRI volumes of the caudate and 
gyrus rectus at the clinical onset of the diseases. Following the longitudinal evolution (1-2 years), 
many brain areas decrease in volume in dementia patients more than in healthy subjects, but only 
the volume of orbitofrontal cortex can discriminate between AD and FTLD, as the decrease is 
greater in FTLD. Even if White Matter (WM) volume reduction is greater in FTLD than in AD, this 
effect is not significant and cannot be used to distinguish them. While FTLD has a greater Grey 
Matter (GM) atrophy rate per year (3.6% FTLD, 2.5% AD, 1% healthy controls), just as with WM 
volume reduction this values is not robust enough to be used in diagnosis, and the volumes at the 
onset of the disease seem to be the more useful discriminant index. 
A simple qualitative scale 
26
 measuring atrophy (0-4, 0 = no atrophy, 4 = severe atrophy) showed a 
good potential in the differentiation between different pathological forms (accuracy 75-84%) and 
between controls, ALS and FTLD patients (accuracy 81-95%). The areas to be analyzed with this 
rating scale are the motor cortex, cingulate cortex, orbitofrontal cortex and anterior temporal cortex. 
Higher atrophy values characterize all FTLD forms, with more marked orbitofrontal atrophy (but 
less marked in motor areas) in bvFTD, and with the opposite pattern in FTD-ALS. In ALS, only the 
atrophy of the orbitofrontal cortex is evident in ALS, and to a lesser extent than in bvFTD. In 
general, atrophy is more widespread in bvFTD than in ALS when considering non motor areas 
27
. 
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SPECT and PET usefulness in differential diagnosis of dementia is ascertained 
28
, and their ability 
to discriminate between different disorders can be greater than MRI, as shown by a study that 
examined 160 patients diagnosed with FTLD, AD or vascular dementia 
29
. A frontal 
hypometabolism or hypoperfusion could help in distinguish between FTLD and AD. Recent 
reviews 
28,30
, that compared 342 AD and 112 FTLD patients calculated that PET has 98-99% 
sensitivity and 65-85% specificity, while for SPECT the values are 72-80% (sensitivity) and 78-
81% (specificity), computed on 480 AD and 158 FTLD patients. When extending the patients 
groups to include DLB, PET ratings drop to 71% for sensitivity and 65% for specificity 
28
.  
There are not many experiments comparing PET and SPECT on the same patients: even if PET 
seems to be a slightly better technique (better spatial resolution), the answer is not conclusive and 
SPECT has the advantage of being the less expensive of the two exams. It has been shown that the 
agreement rate between the exams at a 18 months follow-up could be as good as 90% 
31
. In order to 
maximize the diagnostic ability, it is advisable 
32
 to acquire simultaneously PET/SPECT images 
with high resolution anatomical images (CT or MRI), and use semi quantitative or quantitative 
analysis to compare the patients scan with control groups matched for age and sex. In Italy and 
other countries, the current laws do not allow the use of ionizing radiation on healthy subjects, and 
therefore often a center cannot acquire in house normative control data. It is however possible to 
use data gathered in different foreigner centers, losing about 10% of accuracy. This loss can be 
partially recovered using a spatial normalization procedure that can compensate for the signal 
difference between different scanners 
33
.  
The quantitative analysis should be also carried out with groups of patients diagnosed with different 
disorders, as it is possible to find atypical forms of non-FTLD dementia that can imitate perfusion 
patterns typical of FTLD, as it is shown in a study 
34
 that found in the cerebrospinal fluid (CSF) of 9 
out of 43 patients diagnosed with FTLD a protein pattern suggestive of AD. Also in AD there was a 
frontal hypoperfusion pattern when compared to healthy subjects, but when compared only with 
FTLD patients the area of hypoperfusion was more posterior 
34
. Even if in current practice the 
12 
 
request for a SPECT/PET scan is not accompanied by clinical or cognitive data, including this 
information in the statistical analysis or in the criteria to choose the control group can improve the 
precision of quantitative analysis. In fact, a SPECT study 
35
 carried on 23 FTLD patients (13 with 
episodic memory deficits) found that the metabolic alterations correlated with the clinical severity 
of the disease, and the temporal lobe was more severely damaged in the group with memory 
deficits.  
Cerebral WM is very anisotropic (that is, it has properties that depend on the direction along which 
they are measured, as for example wood, which is easier to split along its grain than against it), 
because axon are gathered in compact bundles, which form tracts with precise spatial orientation. 
By indirectly measuring the water diffusion in cerebral tissues it is possible to obtain estimates of 
WM anisotropy and reconstruct images of the principal tracts. Different techniques allow to 
reconstruct WM bundles starting from diffusion weighted images, and FA (fractional anisotropy) 
and MD (mean diffusivity) are among the most common index, calculated using the DTI model 
(Diffusion Tensor Imaging). When the bundles are altered by microstructural damages, dysfunction 
of axonal organization or by fiber loss caused by Wallerian degeneration, their FA decreases and 
their MD increases. Dementia patients and healthy controls can be clearly discerned using DTI 
metrics; furthermore, different dementias have different characteristic patterns: in FTLD damaged 
areas are more anterior and in AD more posterior 
36
. The anterior cingulate showed a decreased FA 
in bvFTD patients, which correlated with executive deficits, while the posterior cingulate showed a 
decreased FA in AD patients, correlating with visual working memory deficits 
37
. 
A study considering 74 FTLD and 19 AD, classified by CSF protein pattern, comparing the 
diagnostic potential of studying WM microstructure and GM volumes, found that adding WM data 
increases both the sensibility and specificity of the exam from 81% to 89% 
38
. Another study 
showed that the analysis of the only cingulum WM bundle can be at least as indicative that studying 
GM volumes 
39
.  
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A particularly interesting neuroimaging metric is the Loss in Connectivity (LoCo), a measure that 
integrates the information from GM atrophy pattern and microstructural WM alteration in a single 
informative index 
40
. LoCo calculates the percentage of altered WM bundles starting from cortical 
regions involved in FTLD and/or AD (orbitofrontal and subcortical for FTLD, temporo-parietal for 
AD). 
Studying WM integrity provides an excellent characterization of FTLD subtypes, especially the 
different forms of PPA, as in this illness linguistic deficit correlate with alterations of specific WM 
tracts 
41–43
.  
WM damage patterns generally partially border on GM ones, even if in FTLD it is more 
widespread, with a bilateral frontal involvement in bvFTD, asymmetric fronto-parieto-temporal in 
nfPPA, fronto-temporal in svPPA, fronto-parietal in lvPPA 
44
. In FTD-ALS there is a pattern of 
WM and GM damage that lies roughly halfway between bvFTD, in which the damage to fronto-
temporal cortex areas and WM bundles is greater, and ALS with a greater impairment of motor 
areas and bundles 
45
. 
In bvFTD patients the corpus callosum shows widespread damage, while in svPPA the damage is 
limited to a small portion of the genu 
46
. Damage in both svPPA and lvPPA is lateralized to the left 
hemisphere, but can be told apart for the different magnitude of damage in the dorsal and ventral 
systems, as in svPPA 
47
 the damage is particularly evident in the uncinate fasciculus (that joins 
frontal and temporal areas), while in lvPPA the damage is more localized to the posterior part of 
corona radiata 
48
. The damage of aslant tract (a bundle that joins Broca’s area with cingulate cortex 
and supplementary premotor areas) is typical of nfPPA 
47,49
. 
While linguistic production deficits correlate with alterations of frontal WM bundles (e.g. aslant 
tract), integrity of perisilvian areas and of their connectivity is crucial for syntactic processes 
50
. 
Semantic deficits and comprehension impairment are correlated with alterations of the uncinate 
fasciculus 
47–49
. Also the superior longitudinal fasciculus (SLF that joins temporo-parietal and 
frontal areas) and inferior longitudinal fasciculus (ILF that joins occipital and temporal areas) show 
14 
 
differences in PPA: FA is decreased in the SLF in nfPPA, in the ILF in svPPA, while in lvPPA it is 
more similar to normal controls 
51
. 
Even if the patterns described in this section are reliable when performing statistical analysis at 
group level, superposition of different patterns are widespread and partially overlapping in different 
subtypes of FTLD 
52–54
. However, a study 
55
 enrolling 9 svPPA, 9 nfPPA and 9 AD found that at 
least in some cases DTI metrics can be accurate enough to support a diagnosis at single patient 
level. 
Patients neuroimaging characterization  
Functional characterization of FTLD allowed examining neural correlates of the main deficits 
observed in clinical practice: impaired emotion judgment, socially inadequate behavior, apathy, 
impaired mnestic functions and a general deficit in social skills. 
Three different theories about the neural correlates of emotional processing have been investigated 
from the point of view of FTLD research 
56
: the right hemispherical specialization theory, the limbic 
system theory and the multimodal theory, which hypothesizes a network of brain areas in which 
some hub are specific for the elaboration of a specific emotion (e.g.: orbitofrontal cortex for anger, 
amygdala for fear, etc…). Recognition of faces that express emotions is usually damaged in bvFTD 
and svPPA, but are much more spared in nfPPA 
56
. These deficits could be explained by temporal 
atrophy and especially atrophy of the fusiform gyrus, which is specialized in the elaboration and 
recognition of human faces, but the results reach statistical significance even when controlling for 
the decrease in the perceptual skills of patients. This finding is compatible with both hemispheric 
and limbic theories, as these areas are damaged in bvFTD and svPPA but relatively spared in 
nfPPA, but the differences in recognizing single emotions only partially agree with the multimodal 
model. It must however be recalled that a distribute network damaged in an important node could 
have similar deficits, regardless of the specific task of the damaged location. 
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A recent fMRI study that enrolled 20 FTLD 
57
, partially agreeing with limbic and multimodal 
theories, found hypoactivation of the limbic system, fusiform gyrus, occipital cortex, prefrontal 
ventral cortex and insula in patients when they were watching faces showing disgust. 
In another study the authors identified areas that in healthy subjects are synchronized with different 
areas of the amygdala, an important area in emotion processing 
58
. They found that ventral 
amygdala is functionally connected with a network specialized in perception (including the fusiform 
gyrus and orbitofrontal cortex), medial amygdala is functionally connected with a network that 
includes the nucleus accumbens and is specialized in elaborating reward and gratifying stimuli, and 
the dorsal amygdala is connected with a network specialized in elaborating painful and unexpected 
stimuli (the so called Saliency Network, SLN, that includes the medial cingulate cortex and anterior 
insulae). Measuring the volume of the three networks in 20 FTLD patients, the authors found that 
they correlate specifically with different deficits: the pleasure network correlated with 
socioemotional withdrawal and inappropriate behavior, the SLN correlated with an inappropriate 
level of trust and the perceptual network with difficulties in recognizing and attending to social 
clues. 
The link between orbitofrontal and medial prefrontal cortex dysfunctions and inadequate behavioral 
inhibition is highlighted by two PET and two Voxel Based Morphometry (VBM) studies 
59
. It must 
however be considered that using different neuropsychological tests or behavioral measures can 
change significantly the results: therefore, the need to develop more reliable and simple tests, useful 
in differential diagnosis and that correlate robustly with neurobiological data. The Hayling Sentence 
Completion Test (which asks to complete a set of sentences with nonsense conclusions, suppressing 
the automatic answer, as in “The captain wanted to stay with the sinking… banana”) was found to 
be adequate 
59
, as it correlates with orbitofrontal cortex atrophy and can distinguish FTLD and AD 
in clinical practice. 
Other interesting studies found correlations between basal ganglia and frontotemporal cortex 
volumes and apathy 
60
, mind reading 
61
 and overstatement of personal skills 
62
. The impairment in 
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self-monitoring correlates with the volume of the aforementioned areas only when considering 
overstatement in the judgments of self and not understatement 
62
. Atrophy of specific subsystems 
correlates with specific monitoring functions: self-monitoring of emotional control correlates with 
orbitofrontal atrophy 
62
, and empathic worries with the atrophy of anterior and polar temporal areas 
63
. 
The social context network model (SCNM) suggests that the integration of the frontal (which is 
responsible for context analysis and predicting the future) and temporal cortex (semantic storage of 
context), mediated by the insula (comparing the external environment with internal models) could 
be crucial in identifying others’ states of mind and emotions 64. A study recruiting 12 bvFTD and 10 
nfPPA agrees with SCNM, as in nfPPA these skills were more severely damaged and atrophy of 
fronto-temporal-insular cortex was more evident 
65
.  
Mnestic abilities are impaired in FTLD patients, and even if the characteristics of the damage and 
atrophy patterns are usually different from AD, in some cases there is significant overlap between 
clinical symptoms of the two pathologies. For instance, in working memory tasks the performance 
can be equally impaired in AD and FTLD, as this function has its neural correlates in a fronto-
parietal executive network which can be dysfunctional both when the damage is localized to a 
frontal node (as in FTLD) and when it is localized to a parietal one (AD), even if must be noted that 
the qualitative aspects of the deficits in AD and FTLD are quite different 
66
. The differences have 
been the object of a study 
67
 that enrolled 22 bvFTD, 32 AD and 35 healthy controls and tried to 
correlate GM volumes with the scores obtained in specific neuropsychological tests. The scores in 
word list learning, immediate and delayed recall and recognition with or without interference 
correlated with temporal areas in both AD and bvFTD, while frontal functions as verbal fluency, 
verbal working memory and spatial working memory correlated with volumes of dorsolateral 
frontal cortex; other frontal functions as behavioral inhibition, risk assessment and recognition of 
emotions correlated with ventral medial frontal cortex. While memory and ‘lateral’ functions 
deficits are present both in AD and FTLD (with a non-significant trend indicating greater 
impairment in AD), ‘medial’ deficits are typical of bvFTD 67, as striatal dysfunction in associative 
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learning 
68
. Even if the impairment of memory is of a similar magnitude in the two groups, it has 
been associated to different patterns of atrophy and possibly to two different mechanisms 
67
.  
A recurring theme in the study of dementias is the analysis of a group of brain areas functionally 
integrated in fronto-striatal networks 
69
. This line of study tied to characterize the functional 
correlates of social, cognitive and emotive deficits.  
Recently 
70
 it has been observed that some cerebral alterations can be identified also by studying the 
resting connectivity (or synchrony), as measured in Resting State imaging. In particular, the 
connectivity in the frontal executive networks is reduced, even when controlling for the atrophy 
found in FTLD. The SLN, important in the detection of highly salient and unexpected external 
stimuli (Figure 2) showed a reduction in connectivity, as previously stated by other studies 
71
, while 
the medial prefrontal cortex was hyperconnected, especially in bvFTD patients. The authors 
proposed a frontolimbical disconnection accompanied by a maladaptive (it correlated with index 
such as disinhibition and apathy) frontal hyperconnection, possibly due to the lack of the input from 
the limbic system 
70
. This finding was in agreement with a recent paper 
72
 that tried to estimate the 
number of von Economo neurons in the anterior cingulate cortex (ACC), and found a more 
significant decrease in FTLD patients than in healthy controls and AD patients. The difference 
between AD and FTLD patients is only significant in the early stages of the pathology, and there is 
no difference when considering the pathological subtypes (it must be noted that the groups were 
very small). This could mean that VEN are attacked by a common final pathway in all 
proteinopathies and selectively hit in the early stages or, alternatively, that counting VEN is more 
difficult in the late stages and the higher vulnerability of frontal areas compared to the posterior 
ones can explain the relative difference in the loss of VEN, as these neurons are present in greater 
numbers in the cingulate cortex and anterior insulae, both nodes of the SLN system (Figure 1). 
Graph theory, a mathematical technique used to study the structure of sets of connected objects (i.e., 
neural areas that compose a network) can help in the study of dementias by identifying the areas 
involved in a great number of connections (hub) and the type of the connection itself (long or short 
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range). Using this approach it was shown 
73
 that the structure of Resting State connectivity is 
damaged in bvFTD patients, in which only hubs located in the posterior areas were spared. 
Furthermore, disruption of the frontal network correlates with dysexecutive deficits. 
The Default Mode Network (DMN, Figure 1) is composed by areas that are generally more 
activated during rest, symmetrically to the Executive Control Network (ECN, Figure 1), which is 
most active when we turn our attention externally in an active task. The DMN areas are also 
activated when we project ourselves, for example, imagining, simulating a future situation, trying to 
put ourselves in the perspective of others 
74
. The DMN undergoes to opposite alterations in AD and 
bvFTD: the posterior nodes are progressively unconnected in AD and hyperconnected in bvFTD 
74
. 
 
 
 
Figure 2. Intrinsic Networks of brain Resting State showed the main nodes in orthogonal projections (first 
row) and schematic flatted representation (second row). SLN = Salience Network, DMN = Default Mode 
Network. ECN = Executive Control Network. Adapted from 75. 
 
The deficits observed during the Resting State, sometimes quite specific, are particularly useful, as 
they can be measured even in non-cooperating patients and in patients with behavioural alterations, 
and might be seen as fingerprints of different forms of dementia 
75
. Furthermore, it was noted 
76
 that 
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the main neurodegenerative patterns of FTLD and AD are uncannily similar to the networks 
identified with graph analysis in healthy control subjects. 
It has been suggested 
77
 that if neurodegeneration selectively damages the intrinsic connectivity 
network found in healthy subjects, then it is possible that the proteins responsible for the neural 
damages do actually “travel” along these networks during the evolution of the disease. It is 
therefore of the utmost importance to track the spreading of proteinopathies inside the networks 
(Figure 1) in order to understand and identify the most probable mechanism of transmission: prions-
like, lack of tropism, cell signalling, axonal transport, selective vulnerability of some cells or 
connections. 
This ‘deep phenotyping’ of the evolution of dementias from the network graph analysis perspective 
has been called the study of molecular nexopaties (from Latin nectere, tie). The study of the 
characteristic of the spreading of the disease is particularly important: from the initial damage of a 
node, the illness spreads and impairs other nodes using long connections or short ones? Does the 
spreading have a gradient (for instance between the two hemispheres)? Is there a global change of 
the whole network or a gradual transmission from the entry point? The answer to these questions 
could shed light on the nature of the mechanisms of diseases transmission. For example, a large 
database of healthy subjects Resting State were analyzed using the graph-analysis of the intrinsic 
connections searching for pattern of connectivity with the greatest capacity to recapitulate the 
pattern of neurodegeneration of AD, bvFTD, nfPPA, svPPA, CBS 
78
. The processes of disease 
spreading could be mediated by one (or more) of the following alternative mechanisms linked to 
different kind of connectivity profiles: 
1) Lack of neurotrophism = vulnerability of the less connected nodes;  
2) Neurotransmitter-mediated spreading = vulnerability of ‘epicenter’ nodes, characterized by 
short-distance links with all other nodes; 
3) Specific vulnerability of the hubs, due to the elevated connection activity; 
4) Vulnerability of neural subpopulations, not linked to specific topological correlates.  
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The results of the study lend support to the second hypothesis 
78
. 
New neuroimaging tools 
ASL is a relatively recent MRI technique that in the last years has evolved enough to be considered 
for use in clinical practice. Its working principle is simple: it inverts the signal of the water inside 
the arteries and labels it, thereby creating an “endogenous marker”. Labeled blood perfuses the 
brain and the signal generated by brain tissues added to the signal of the blood flowing is acquired. 
A second scan acquires an image of the brain without labeling the blood, and the two images are 
subtracted to each other to obtain an estimate of blood perfusion 
79
. In a consensus paper Alsop and 
collaborators suggested the optimal parameters (pseudo-continuous labelling, background 
suppression, 3D segmented reading and quantitative analysis) to use ASL in clinical practice, in 
order to keep homogeneity and comparability between studies 
79
. Using ASL it is possible to obtain 
perfusion weighted images, like when using Nuclear Medicine techniques, without the use of 
ionizing radiations. Comparing ASL and perfusional SPECT on 68 patients with suspected AD, a 
paper 
80
 found that the two techniques reach a similar accuracy, even if ASL is more prone to errors 
due to the greater influence of hemodynamic factors (accounting for 70% of misdiagnosis). 
Furthermore, in ASL the patterns of MRI hypoperfusion, cerebral atrophy and WM alterations 
reach a good level of agreement, as shown by a multimodal study using ASL, DTI and VBM on 20 
AD, 20 FTLD and 21 control subjects 
81
. Other studies showed that ASL can distinguish reliably 
between FTLD, DLB and AD 
82
 and that its results can be used as useful functional correlates in 
research 
83
. 
The set of possible new radiopharmaceuticals is quite large, and it is likely that the next years will 
see the discovery of new tracers with useful applications in the diagnosis of dementia. The 
development of new in vivo measures, directly linked to neuropathological correlates is of 
particular interest. To this day, two radiopharmaceuticals that can label β-amyloid plaques have 
been developed: Pittsburgh compound B (11C-PiB) and Florbetapir(18F), or 18F-AV-45. While 
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plaques are typically associated with AD, combining β-amyloid imaging with PET-FDG can 
increase the potential of differential diagnosis. In 154 patients, mostly affected by AD, FTLD and 
DLB, labeling amyloid plaques was found to be useful in reconsidering some uncertain diagnosis. 
FDG alone is usually enough to reach a diagnosis, but as atypical cases are more likely to be 
misdiagnosed, an exam using PiB as tracer can be useful. Furthermore, being positive for both PiB 
and FDG can predict the progression of patients to dementia, and the diagnosis formulated on the 
grounds of the results of this exams are not changed in 96% of cases 
84
 at 2 years follow-up.  
Between other radiopharmaceuticals in development, the ones that can be used to perform 
neuroimaging of inflammation are of particular interest. These molecules map the translocator 
protein 18 kDa (TSPO): 18F-PBR111, 11C- 18F- PBR06, 11C- 18F- PBR28 and 18F-FEPPA 
85
, 
and allow the clinician to have a map of microglia activation, linked with the inflammatory 
response both in time and space.  
Other molecules [18F]-T807, [18F]-T808, [18F]-THK5105 and [18F]-THK523 
85
 can label the 
accumulations of tau protein and are therefore of particular interest as are other 
radiopharmaceuticals currently in development, that should be able to mark selectively the enzymes 
involved in the biological pathways that create the anomalous protein accumulations 
85
. 
Another research branch is focused on the development of new radiopharmaceuticals able to label 
the receptors of neurotransmitters, selectively involved in different dementia types. An example of 
this approach is the use of molecules like 123I-FP-CIT, 123I-β-CIT, previously only used in 
Parkinson-like diseases. This could be useful as dopaminergic neurons of basal ganglia are 
compromised in different ways in AD, FTLD and DLB: in the majority of DLB cases there are 
alterations, as in about 50% of FTLD cases, while in AD they are almost always absent. FP-CIT can 
therefore be used to exclude DLB, even if this evidence is not always strong enough to discriminate 
between FTLD and AD 
86
. False positives and negatives can be due to drug intake or vascular 
problems in suspected dementias 
87
.  
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Presymptomatic patients 
One of the most interesting aspects in the study of patients carrying a mutation linked to FTLD is 
the possibility of studying in vivo the evolution of subjects before the pathology becomes clinically 
relevant and thus to identify which biomarkers can better predict the onset of the disease and 
monitor the response to experimental pharmacological treatments 
88
. Studies on presymptomatic 
patients are still in a very early stage, but some authors found what could be an important result: 
similarly to presymptomatic familiar AD patients, also in FTLD functional alterations in perfusion 
89
 or Resting State 
90
, similar to the ones found in symptomatic patients, could be present in 
asymptomatic patients many years before the onset of the illness. However, it must be noted that no 
one still found truly significant alterations in GM or WM, and that the sample sizes were too small 
to draw conclusions at the current stage.  
It should also be noted that a study 
91
 found in asymptomatic subjects carriers of the MAPT 
mutation alterations in the values of MI and NAA. The values found in asymptomatic subjects, 
years before the disease onset, were roughly halfway between the ones of healthy subjects and of 
patients with diagnosed dementia. 
During the last years new imaging techniques in the diagnosis of dementias have been investigated 
by a number of papers, thus opening new diagnostic approaches to these illnesses. In particular, the 
techniques more often investigated are the study of microstructural and axonal integrity of WM 
(DWI) and functional correlates (fMRI, Resting State) of functions damaged by FTLD. 
Furthermore, recent advances in a MRI technique able to obtain perfusional weighted images, 
called Arterial Spin Labelling (ASL), brought it to the point of being comparable with perfusional 
SPECT. ASL advantage over the latter is the absence of ionizing radiations and of their noxious 
effects; therefore, it is a significant improvement for patients, especially when they are being 
monitored for years to follow the evolution of a degenerative disease. 
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Conclusions 
While the current approach to the study of dementias is mostly focused on mapping and correlating 
atrophy of cerebral areas and cognitive functions, the results are often as elaborate as they are 
unreliable because of the variability in forms and manifestations of dementia and the relatively high 
variance in the atrophy patterns. A better approach would be to focus on the possible treatments for 
the different syndromes, and link with a rational and well-thought master plan the different aspects: 
genetics, clinical observations and etiopathology. 
Neuroimaging techniques have shown to be useful supporting tools in diagnosis, even if not always 
determinant to reach a conclusive decision, and quite important to identify phenocopies. Future 
neuroimaging studies should strive to include at least CSF data, and possibly also genetic and 
pathological information, in order to avoid grouping patients with different (misdiagnosed) 
pathologies. 
At the moment there is not a neuroimaging biomarker that could track the progressive course of 
dementias and the effect of therapies, but it is possible that in the future DTI and molecular imaging 
could fill this void. Monitoring in vivo the evolution of the pathology is essential, but to the best of 
our knowledge no study embarked in this huge effort (ideally, ASL, volumetry, Resting State and 
DTI every 3 months for at least 5 years on a large and well-defined group of patients, plus 
neuropsychological testing, clinical observation and CSF analysis), which would only be possible in 
a large multicentric study, while asymptomatic forms would require even longer observation 
periods. 
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